Intercept Pharmaceuticals Competitors and Similar CompaniesClear all
Intercept Pharmaceuticals's competitors and similar companies include Ipsen and CSL Behring.
 Intercept Pharmaceuticals Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases. | |||
Founding Date | Founding Date 2002 | Founding Date 1929 | Founding Date 1904 |
Type | Type Public | Type Public | Type Subsidiary |
Tags | |||
Locations | Locations New York, US HQ Wien, AT Mississauga, CA Kongens Lyngby, DK Paris, FR München, DE Dublin, IE see more | Locations Boulogne-Billancourt, FR HQ Algiers, DZ South Yarra, AU Wien, AT Merelbeke, BE São Paulo, BR Mississauga, CA see more | Locations King of Prussia, US HQ Broadmeadows, AU Parkville, AU Parkville, AU Wien, AT Mechelen, BE see more |
Employees | Employees 58321% increase | Employees 5,358 | Employees 7,5692% decrease |
Valuation ($) | Valuation ($) 794.7 m | Valuation ($) 10.2 b | Valuation ($) N/A |
Financial | |||
Revenue (est.) | Revenue (est.) $285.7m (FY, 2022) | Revenue (est.) €3.7b (FY, 2025) | Revenue (est.) $7.9b (FY, 2020) |
Cost of goods | Cost of goods $984k (FY, 2022) | Cost of goods €659.1m (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit $284.7m (FY, 2022) | Gross profit €3.3b (FY, 2025) | Gross profit $4.5b (FY, 2020) |
Net income | Net income $221.8m (FY, 2022) | Net income €445.1m (FY, 2025) | Net income N/A |
For sources of this data, please see the company profile